CAS 937272-79-2

Pacritinib

Description:

Pacritinib is a small molecule inhibitor primarily used in the treatment of certain hematological malignancies, particularly myelofibrosis. It selectively targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3), which are involved in the signaling pathways that regulate cell proliferation and survival. This selective inhibition helps to mitigate the symptoms associated with myelofibrosis, such as splenomegaly and constitutional symptoms. Pacritinib is characterized by its oral bioavailability and a unique pharmacokinetic profile, allowing it to be administered without the need for dose adjustments in patients with varying degrees of liver impairment. The compound has been studied for its efficacy and safety in clinical trials, demonstrating a favorable response in patients who have previously been treated with other therapies. As with many targeted therapies, potential side effects may include thrombocytopenia, anemia, and gastrointestinal disturbances, necessitating careful monitoring during treatment. Overall, Pacritinib represents a significant advancement in the therapeutic options available for patients with myelofibrosis.

Formula: C₂₈H₃₂N₄O₃

InChI: InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+

InChI key: InChIKey=HWXVIOGONBBTBY-ONEGZZNKSA-N

SMILES: O(CCN1CCCC1)C=2C3=CC(N=C4NC(C=5C=C(C=CC5)COC/C=C/COC3)=CC=N4)=CC2

Synonyms:

• 14,19-Dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-[2-(1-pyrrolidinyl)ethoxy]-, (16E)-
• (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene
• SB 1518
• Pacritinib

(16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene

CAS: 937272-79-2

Formula: C₂₈H₃₂N₄O₃

Purity: 97%

Color and Shape: Solid

Molecular weight: 472.5787

Ref: IN-DA003A49

Pacritinib

CAS: 937272-79-2

Pacritinib

Purity: ≥95%

Molecular weight: 472.58g/mol

Ref: 54-BUP10115

Pacritinib

CAS: 937272-79-2

Formula: C₂₈H₃₂N₄O₃

Molecular weight: 472.59

Ref: 4Z-P-485001

Pacritinib

CAS: 937272-79-2

Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).

Formula: C₂₈H₃₂N₄O₃

Purity: 99.25% - 99.49%

Color and Shape: Solid

Molecular weight: 472.58

Ref: TM-T6020

Pacritinib

Controlled Product

CAS: 937272-79-2

Formula: C₂₈H₃₂N₄O₃

Color and Shape: Neat

Molecular weight: 472.579

Ref: TR-P133700

Pacritinib

CAS: 937272-79-2

Pacritinib is a selective inhibitor of the tyrosine kinase JAK2. It has been shown to be effective against colorectal adenocarcinoma, hepatic steatosis, and minimal toxicity in preclinical trials. Pacritinib inhibits the activity of JAK2, which is an enzyme that participates in the signaling pathways of cytokines and growth factors that are involved in immune responses and cell proliferation. This drug may have potential for the treatment of infectious diseases, such as tuberculosis and leishmaniasis, as well as autoimmune diseases such as psoriasis and rheumatoid arthritis. Pacritinib is currently undergoing clinical trials for the treatment of various types of cancer, psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, and other immune-mediated disorders.

Formula: C₂₈H₃₂N₄O₃

Purity: Min. 95%

Molecular weight: 472.59 g/mol

Ref: 3D-MMB27279